Related Experiment Video
Updated: Mar 6, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.6K
Immune Checkpoint Inhibitors in Gliomas
Aaron C Tan1, Amy B Heimberger2, Mustafa Khasraw3
1Northern Sydney Cancer Centre, Royal North Shore Hospital, Reserve Rd, St Leonards, NSW, 2065, Australia.
Current Oncology Reports
|March 18, 2017
Summary
Novel therapies, including immune checkpoint inhibitors, show promise for treating malignant gliomas, a deadly brain tumor. Biomarkers are crucial for identifying responsive tumors and guiding future clinical trials.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer research
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Current treatments for malignant gliomas have limited efficacy, necessitating novel therapeutic approaches.
- Immune checkpoint inhibitors represent a promising avenue for improving outcomes in glioma patients.
Purpose of the Study:
- To review the potential of immune checkpoint inhibitors as a novel therapy for malignant gliomas.
- To discuss essential biomarkers for identifying glioma subtypes responsive to immune checkpoint inhibitors.
- To highlight the evolving evidence and future directions for immunotherapy in glioma treatment.
Main Methods:
- Review of preclinical evidence on immune checkpoint inhibitors in glioma models.
- Analysis of potential biomarkers, including mismatch repair deficiency and high mutational load.
- Discussion of ongoing and future clinical trials investigating immune checkpoint inhibitors for gliomas.
Main Results:
- Preclinical data suggest immune checkpoint inhibitors may be effective against gliomas.
- Biomarkers such as mismatch repair deficiency and high mutational load are critical for predicting treatment response.
- Evidence for immune checkpoint inhibitors in gliomas is still emerging, with clinical trials underway.
Conclusions:
- Immune checkpoint inhibitors hold significant promise as a novel treatment strategy for malignant gliomas.
- Identifying predictive biomarkers is essential for maximizing the efficacy of these therapies.
- Further research and well-designed clinical trials are crucial to establish the role of immune checkpoint inhibitors in glioma management, potentially in combination with other treatments.
